Literature DB >> 19152070

Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting.

Asit K Paul1, Michael J Ciesielski, Munawwar Sajjad, Xinhui Wang, Soldano Ferrone, Hani Abdel-Nabi, Robert A Fenstermaker.   

Abstract

Human melanoma proteoglycan (HMP), a melanoma-associated antigen, is expressed in both human melanomas and gliomas. We used HMP-specific monoclonal antibody (mAb) VT68.2 to investigate whether murine GL261 cerebral gliomas express the HMP homologue AN2 and to determine whether AN2 could be targeted for selective delivery of radiation in vivo. HMP-specific mAb VT68.2 stained murine GL261 glioma cells grown in culture and intracerebrally in syngeneic C57BL/6 mice. Positron emission tomography with radiolabeled mAb VT68.2 showed high-contrast, positive images of gliomas against a negative background. At 96 h after injection, glioma uptake of radiolabeled mAb VT68.2 was 10x greater than that of the isotype control mAb and 20x greater than that detected in normal cerebral tissue. Our results show murine GL261 cerebral gliomas express AN2 and HMP-specific mAb VT68.2 accumulates selectively and specifically at high concentration and is retained within murine cerebral gliomas. Thus, HMP is a potential target for antibody-mediated selective delivery of radiation to cerebral gliomas in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19152070      PMCID: PMC2741310          DOI: 10.1007/s11060-009-9798-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology.

Authors:  Soonmee Cha; Glyn Johnson; Youssef Zaim Wadghiri; Olivier Jin; Jim Babb; David Zagzag; Daniel H Turnbull
Journal:  Magn Reson Med       Date:  2003-05       Impact factor: 4.668

2.  NG2-expressing glial progenitor cells: an abundant and widespread population of cycling cells in the adult rat CNS.

Authors:  Mary R L Dawson; Annabella Polito; Joel M Levine; Richard Reynolds
Journal:  Mol Cell Neurosci       Date:  2003-10       Impact factor: 4.314

3.  NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin.

Authors:  Martha Chekenya; Mari Hjelstuen; Per Øyvind Enger; Frits Thorsen; Anne L Jacob; Beatrice Probst; Olav Haraldseth; Geoffrey Pilkington; Arthur Butt; Joel M Levine; Rolf Bjerkvig
Journal:  FASEB J       Date:  2002-04       Impact factor: 5.191

4.  The NG2 chondroitin sulfate proteoglycan: role in malignant progression of human brain tumours.

Authors:  M Chekenya; H K Rooprai; D Davies; J M Levine; A M Butt; G J Pilkington
Journal:  Int J Dev Neurosci       Date:  1999 Aug-Oct       Impact factor: 2.457

5.  Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.

Authors:  Marianela Candolfi; James F Curtin; W Stephen Nichols; Akm G Muhammad; Gwendalyn D King; G Elizabeth Pluhar; Elizabeth A McNiel; John R Ohlfest; Andrew B Freese; Peter F Moore; Jonathan Lerner; Pedro R Lowenstein; Maria G Castro
Journal:  J Neurooncol       Date:  2007-09-15       Impact factor: 4.130

6.  124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.

Authors:  Gobalakrishnan Sundaresan; Paul J Yazaki; John E Shively; Ronald D Finn; Steven M Larson; Andrew A Raubitschek; Lawrence E Williams; Arion F Chatziioannou; Sanjiv S Gambhir; Anna M Wu
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

Review 7.  AN2, the mouse homologue of NG2, is a surface antigen on glial precursor cells implicated in control of cell migration.

Authors:  Judith Stegmüller; Stephanie Schneider; Andrea Hellwig; Jeremy Garwood; Jacqueline Trotter
Journal:  J Neurocytol       Date:  2002 Jul-Aug

8.  Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.

Authors:  Robert M Prins; Sylvia K Odesa; Linda M Liau
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

9.  The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours.

Authors:  M Chekenya; P Ø Enger; F Thorsen; B B Tysnes; S Al-Sarraj; T A Read; T Furmanek; R Mahesparan; J M Levine; A M Butt; G J Pilkington; R Bjerkvig
Journal:  Neuropathol Appl Neurobiol       Date:  2002-10       Impact factor: 8.090

10.  Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study.

Authors:  C Grana; M Chinol; C Robertson; C Mazzetta; M Bartolomei; C De Cicco; M Fiorenza; M Gatti; P Caliceti; G Paganelli
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

View more
  2 in total

Review 1.  Immunocompetent murine models for the study of glioblastoma immunotherapy.

Authors:  Taemin Oh; Shayan Fakurnejad; Eli T Sayegh; Aaron J Clark; Michael E Ivan; Matthew Z Sun; Michael Safaee; Orin Bloch; Charles D James; Andrew T Parsa
Journal:  J Transl Med       Date:  2014-04-29       Impact factor: 5.531

Review 2.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.